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Abstract
Niemann-Pick disease type C (NPD-C) is a rare neurodegenerative disorder character-
ized by a lysosomal storage disorder. Treatment has been supportive and symptomatic. 
In animal studies, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) showed a significant 
decrease in cerebellar damage, neurological progression, and higher lifespan. Based on 
these results, HP-β-CD has been tested in NPD-C patients for last 8 years. The first 
compassionate uses of intravenous HP-β-CD obtained a limited improvement in neu-
rological symptoms, probably associated to the non-permeation of the blood-brain 
barrier. The change or combination with intrathecal administrations of HP-β-CD 
achieved higher benefits, especially improvement or stabilization of NPD-C progres-
sion. Biomarkers of neurological cholesterol homeostasis are being investigated in order 
to quantify the response of HP-β-CD treatment. The results of a clinical trial recently 
published have reproduced the slowing of NPD-C progression in 14 patients treated 
with a dose-escalation protocol of HP-β-CD intrathecal monthly infusions, with respect 
to a historical comparison cohort. The safety profile of this therapy is acceptable, being 
the loss of hearing as the most frequent adverse event. However, some severe toxicities 
have been reported in relation with HP-β-CD, including chemical meningitis and fever. 
The short experience with HP-β-CD suggested that it could be effective in the manage-
ment of NPD-C.
Keywords: Niemann-pick type C, 2-hydroxypropyl-β-cyclodextrin, cholesterol, 
neurodegenerative diseases, blood-brain-barrier
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
1.1. Etiology
Niemann-Pick disease type C (NPD-C) is a rare autosomal recessive disorder characterized by 
lysosomal lipid storage in which faulty intracellular lipid transport leads to accumulation of 
unesterified cholesterol and glycosphingolipids in several neurovisceral tissues [1, 2].
NPD-C is caused by mutations in either the NPC1 or NPC2 genes. The NPC1 gene, located on 
the long arm of chromosome 18 (18q11.2), encodes a large (142 kDa) membrane glycoprotein 
placed in endosomes and lysosomes. This protein mediates intracellular cholesterol traffick-
ing via binding of cholesterol to its N-terminal domain. NPC2 gene, located on the long arm 
of chromosome 14 (14q24.3), encodes a small (16 kDa) lysosomal protein that binds to cho-
lesterol. NPC1 and NPC2 proteins seem to act in the cooperative transportation of molecules 
within cells. Recently, it has been shown, the N-terminal domain of NPC1 protein may interact 
with NPC2 protein to facilitate cholesterol efflux from the late endosome and lysosomes [3, 4].
The majority of patients show mutations in the NPC1 gene (95%), whereas a much smaller 
number suffer mutations in the NPC2 gene, but the resulting phenotypes are clinically indis-
tinguishable. Loss of function of either of these proteins results in an accumulation of cho-
lesterol and other lipids, including sphingomyelin, sphingosine, and gangliosides (GM2 and 
GM3), within the endosomes and lysosome [3, 4].
1.2. Diagnosis
The diagnosis of NPD-C requires a combination of clinical, cellular, and molecular criteria. 
NPD-C is suspected on the basis of the clinical features. Systemic manifestations such as hepa-
tosplenomegaly neonatal, cholestatic jaundice, or splenomegaly can lead to diagnosis, but, 
due to the heterogeneous clinical phenotype, diagnosis is often delayed for many years or 
missed altogether [4]. A Suspicion Index tool might be useful as a screen for NPD-C, a risk 
prediction score ≥70 indicates a strong suspicion for NPD-C [5]. The diagnosis of NPD-C is 
confirmed by biochemical testing that demonstrates impaired cholesterol esterification and 
positive filipin staining in cultured fibroblasts obtained from a skin biopsy. Filipin staining 
demonstrates intense punctate pattern of fluorescence concentrated around the nucleus, con-
sistent with unesterified cholesterol. Molecular genetic testing of NPC1 and NPC2 are com-
mercially available and they detect pathogenic variants in approximately 94% of individuals 
with NPD-C [4].
The filipin assay is unable to provide a firm diagnosis in fibroblasts with “variant” pheno-
types that represent one-third of NPD-C cases. Moreover, the assay is invasive and the results 
can delay for 3 months. Genetic analysis is an important diagnostic tool, though, due to 
cost considerations, generally applied as a confirmatory rather than screening test. In recent 
years have been identified promising NPD-C biomarkers. One of these markers, cholestane-
3β,5α,6β-triol, which is a cholesterol oxidation product, has emerged as a sensitive diagnostic 
for NPD-C [6, 7].
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1.3. Clinical presentation and symptoms of Niemann-Pick disease
Systemic involvement of liver, spleen, or lung, is present in ≥85% of patients, and precedes the 
development of neurologic symptoms. The age of onset and clinical presentation of NPD-C 
is highly variable.
Neonatal and infantile presentations: Occasionally, ultrasound examination in late pregnancy 
has detected fetal ascites; infants thus identified typically have a severe neonatal liver disease 
with jaundice and persistent ascites. Infiltration of the lungs with foam cells can be present. 
Many infants die at this stage. Of children who survive, many have hypotonia and psychomo-
tor retardation whereas others may have complete resolution of symptoms, only to present 
with neurologic disease many years later [4].
Childhood presentations: These patients typically have cerebellar involvement characterized by 
clumsiness and gait problems progressing to frank ataxia and slow cognitive deterioration 
Vertical supranuclear ophthalmoplegia is another early manifestation. Progressive dystonia, 
dysarthria, and dysphagia occur, eventually impairing oral feeding, and approximately one-
third of patients develop seizures [4].
Adolescent and adult presentations: The clinical presentation is similar to childhood onset with 
ataxia, supranuclear vertical gaze palsy, cognitive impairment, except that progression is gen-
erally much slower. Other adults present with cognitive dysfunction or psychiatric distur-
bances as major depression, schizophrenia, or bipolar disorder [4].
1.4. Previous treatments employed
There is no curative treatment for NPD-C. The disease management is individualized and 
it consists mainly of symptomatic treatment. Seizures, dystonia, and cataplexy can respond 
to drugs. Other symptomatic measures like physiotherapy in spasticity, gastrostomy tube 
placement to prevent aspiration and/or inadequate nutrition in patients with progressive dys-
phagia, and bronchoalveolar lavage to improve pulmonary function are useful in the disease 
management. Combination of drug regimens have been shown to lower hepatic and plasma 
cholesterol but there is no evidence that these results affect the progression of the disease in 
humans or murine models. Behavioral and speech problems or schooling difficulties should 
be referred to as psychiatric team and special schooling [8, 9].
To date, miglustat is the only disease-specific drug approved in Europe, Canada, and Japan. 
The drug works by inhibiting the glucosylceramide synthase enzyme that is responsible for 
the first step in the synthesis of most glycosphingolipids. Miglustat has shown to stabilize 
key parameters of neurological disease progression in patients of all ages, but it has no effect 
on the systemic manifestations or intracellular cholesterol accumulation associated with this 
disorder [10].
There is a persistent search for new treatments to prevent or slow down the progression of 
NPD-C. Investigational therapies in course are 2-hydroxypropyl-beta-cyclodextrin (HP-β-CD) 
or hematopoietic stem cell transplantation.
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VTS-270 (Kleptose® HPB, Roquette Pharma, France) and Trappsol® Cyclo™ (CTD Holdings, 
Inc., Alachua, FL) are HP-β-CD products under investigation as novel treatments for NPD-
C. Differences between these two products have been studied based on ion distribution and 
abundance profiles using mass spectrometry methodology as a means to assess key molecu-
lar distinctions between products. Trappsol® Cyclo™ was found to have a higher degree of 
substitution compared with VTS-270, with a greater number of hydroxypropyl groups and 
increased levels of dimeric ions. Additional differences in ion mobility profiles were found, 
there is a much greater level of non-specific chemical “noise” associated with Trappsol® 
Cyclo™.
These two products are not chemically equivalent and therefore may not be biochemically 
equivalent or lead to comparable formulations from a clinical development perspective. The 
data suggest that biological and potential therapeutic equivalence should not be assumed. 
Further studies are needed to examine potential differences in biological and therapeutic 
effects of Trappsol® Cyclo™ and VTS-270 [11].
2. Preclinical studies
2.1. In vitro experience
The efflux of cholesterol from cells in culture to cyclodextrin acceptors has been reported to be 
substantially more rapid than efflux induced by other known acceptors of cholesterol. A com-
parison of the time course of cellular [3H]cholesterol efflux mediated by HDL3 or by various 
concentrations of cyclodextrins showed the release of 50–90% of L cell [3H]cholesterol after 
8 hours of incubation with HP-β-CD and methyl-β-cyclodextrin (M-β-CD) at 10 mM. The 
order of efficiency in accepting cholesterol was found to be M-β-CD > HP-β-CD > beta-cyclo-
dextrin. The kinetics of the cholesterol efflux time course studies suggested that incubation 
of L cells with cyclodextrin resulted in the rapid equilibration of labeled cholesterol between 
cells and medium. [12].
Several studies have shown that cholesterol released from late endosomes/lysosomes of NPC-
proteins deficient cells by HP-β-CD reaches the cytosolic compartment and is accessible to the 
endoplasmic reticulum (ER). In cultured cerebellar neurons, astrocytes, and microglia from 
NPC1-deficient mice, the sequestered cholesterol was mobilized to the ER by low concentra-
tions (0.1–1.0 mM) of HP-β-CD [13].
In murine models of NPC1, cell culture studies have shown that M-β-CD is more potent 
in exchanging cholesterol than HP-β-CD. Efficacy comparison of M-β-CD and HP-β-CD in 
reducing cholesterol accumulation in late endosome/lysosome in human fibroblasts NPC1/
NPC2 deficient after treatment with 300 μM M-β-CD and HP-β-CD for 1 day have shown to 
reduce the cholesterol accumulation detected by filipin labeling. After 2 and 3 days after treat-
ment, cholesterol accumulation started to increase, but there was still a significant reduction. 
In concordance with animal studies, M-β-CD produces effects equivalent to those of HP-β-CD 
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at lower concentrations [14].There are several theories about the mechanism by which cyclo-
dextrins affect cholesterol homeostasis but none have been confirmed.
In vitro beta-cyclodextrins showed a high affinity for sterols as compared to other lipid and, 
because of the relatively high specificity of this substance for cholesterol, it was suggested that 
beta-cyclodextrins might be effective in modifying cholesterol metabolism in vivo.
2.2. Animal studies
The unexpected discovery of the utility of cyclodextrin in NPD-C was observed in a study in 
Npc1−/− mice treated with a combination therapy of two drugs, one of them (allopregnanolone) 
formulated in a cyclodextrin complex [15]. A later study showed the same cholesterol intraneu-
ronal storage reduction and longevity increase with the combination of allopregnanolone and 
cyclodextrin than with the control arm, treated only with the cyclodextrin [16]. These results 
led researchers to perform studies to address the role of cyclodextrin as a possible treatment. 
The Npc1−/− mice receiving subcutaneous (SC) or intraperitoneal cyclodextrin every other 
day for 2 weeks revealed a slight decrease of intraneuronal accumulation of either cholesterol 
or gangliosides. Both routes showed similar outcome, but SC administration seemed to be a 
slightly more efficacious [16]. In another study, Npc1−/− mice treated with a single SC injection 
at 7 days of age of HP-β-CD (4000 mg/kg body weight) prolonged the average life (108 days).
Treatment with cyclodextrin improved hepatic dysfunction and decreased neurodegenera-
tion, increasing the number of Purkinje cells surviving at 49 days of age nearly threefold 
respect to untreated mice [16]. In previous studies, no significant toxicity was observed fol-
lowing the administration of HP-β-CD except for increased macrophage infiltration of the 
lungs found at post mortem examination [16, 17]. Other studies in Npc1−/− mice showed that 
1500 mg/kg HP-BC-D administered weekly caused a decrease in hepatic unesterified choles-
terol concentrations without substantial effect on neurological signs The slight effects of the 
HP-β-CD on neurological symptoms at low doses may be partially due to their apparent non-
permeation of the blood-brain barrier (BBB) [18].
The efficacy of HP-β-CD was also tested in a feline model of NPD-C. Cats affected with 
NPD-C were first administered the drug at 3 weeks of age, prior to the onset of clinical 
signs of disease, and continued to receive the drug weekly. Cats were placed into one of five 
groups: received no HP-β-CD; received a weekly dose of 1000 mg/kg; 4000 mg/kg; 8000 mg/
kg body weight HP-β-CD subcutaneously; or 4000 mg/kg brain weight (120 mg for a 30 g 
brain weight) HP-β-CD intrathecally every 2 weeks. The preliminary data suggested a similar 
requirement for doses equal to or greater than 4000 mg/kg to positively affect neurological 
disease. Nevertheless, doses of 4000 mg/kg body weight resulted in an increase in hearing 
threshold only after repeated dosing and doses of 8000 mg/kg body weight resulted in signifi-
cant increases in hearing threshold in both normal cats and cats with NPD-C following the 
administration of a single dose [19].
Studies in mouse models have shown that systemic administration of HP-β-CD, starting in 
early neonatal life, diminishes unesterified cholesterol accumulation in most organs, slows 
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disease progression, and extends lifespan. Studies in adult Npc1−/− mice who received four 
weekly subcutaneous 4000 mg/kg body weight HP-β-CD at 49 days of age showed reduced 
whole-liver cholesterol content at 77 days. Comparable improvements were seen in other 
organs, such as spleen, and lifespan was extended [20]. On the whole, preclinical studies in 
animals showed that young animals respond more favorably, whereas the older ones may 
benefit less.
Brain uptake of 2-hydroxypropyl-[14 C]-propyl-β-cyclodextrin was determined in Npc+/+ 
and Npc1−/− mice using two methods: in situ brain perfusion and multi-time-point regres-
sion analysis flowing intraperitoneal administration. None of the data collected indicated that 
HP-β-CD enters the brain [21]. Other experiments examining cyclodextrins with regard to 
permeability using an in vitro model of the BBB have indicated that a small percentage of 
cyclodextrin may be transported across the barrier [22].
Intrathecal (IT) HP-β-CD (120 mg in 0.6 ml saline) every 2 weeks therapy of feline NPD-C 
delayed the clinical manifestations of neurological disease, but had no effect on hepatic or 
pulmonary disease. IT-treated cats showed amelioration of neuronal swelling and axonal 
spheroid formation in many but not all brain regions, and preservation of Purkinje cell num-
bers [23]. Research in mouse models of NPD-C also has shown that direct administration 
of HP-β-CD into the IT or intracerebroventricular (ICV) space at low concentrations has a 
similar or superior effect on delaying the onset of neurological symptoms as that observed 
following high systemic doses [24].
Recent researches in NPD-C cats showed that direct administration of HP-β-CD into the 
cisterna magna prevented the onset of cerebellar dysfunction for greater than a year and 
reduced in Purkinje cell loss and near normal concentrations of cholesterol and sphingolip-
ids. Cats receiving 1000 mg/kg SC HP-β-CD had a similar occurrence of neurological dys-
function and survival than untreated cats. Nevertheless, cats that received 4000 mg/kg SC 
HP-β-CD showed modest amelioration of neurological disease and survived age than any 
untreated cats. Pulmonary toxicity limited the continued dosing of cats in the 8000 mg/kg 
group. Dose-dependent elevations in mean hearing threshold in cats receiving SC HP-β-CD 
were observed. In cats receiving intracisternal HP-β-CD, a significant elevation in the audi-
tory threshold was also observed. [25].
3. Experience in humans: first experiences of compassionate use of 
cyclodextrin
Based on the promising results of preclinical studies in animal models of NPD-C, in November 
2008, Dr Hastings applied for individual investigator new drug exemptions (INDs) to the Food 
and Drug Administration (FDA) for the use of with HP-β-CD in humans. In January 2009, the 
first NPD-C patient in the world, an Indian child, was treated with HP-β-CD by intrave-
nous (IV) route. Few months later, the first two INDs of HP-β-CD in USA were approved by 
FDA for two identical twins aged 5-year-old [26]. The “Oakland protocol” of IV HP-β-CD 
employed in USA was also used in two Brazilian sisters with NPD-C in January 2010 [27].
Cyclodextrin - A Versatile Ingredient100
The orphan designation of HP-β-CD was obtained in May 2010 by FDA [28] and 2 months 
later by the European Medicines Agency (EMA) [29]. The orphan drug brand Trappsol® 
Cyclo™ was approved specifically for treating NPD-C. New findings suggested that the pas-
sage of HP-β-CD across the BBB was limited [21, 24, 25, 30], and physicians who treated the 
first patients reported slight benefit with IV route [26]. The FDA approved the request for IT 
delivery of HP-β-CD in September 2010 [31]. Another orphan drug of HP-β-CD was desig-
nated by FDA in February 2013, Kleptose™ (brand VTS-270). Both drugs were being evalu-
ated in clinical trials, moreover compassionate use outside clinical trials has been reported 
worldwide [32].
Five different approaches have been employed in HP-β-CD therapy:
• IV only.
• IT only.
• ICV only.
• IV at the beginning, and later changed to IT or ICV.
• IV and IT simultaneously.
The IV administration was the first route tested for HP-β-CD in humans. When different 
reports in animals demonstrated that HP-β-CD administered intravenously cross in very little 
proportion the BBB [21, 24, 25, 30], this route was changed or combined with IT/ICV adminis-
tration of the same drug. Theoretically, IT and ICV routes deliver directly the drug in the cen-
tral nervous system (CNS), the area mainly affected in NPD-C, especially in the neurological 
symptoms. There is still controversy over whether the IV route contributes in NPD-C therapy. 
Preclinical reports showed effectiveness in the peripheral manifestations of the disease in 
organs [20, 25], including the liver, the spleen, and, to a lesser extent, the lungs. However, the 
influence of HP-β-CD in CNS after IV infusion remains in humans unknown.
4. Experience in humans: efficacy of the intravenous administration 
of cyclodextrin
The first two patients who received IV HP-β-CD (Trappsol® Cyclo™) in USA were treated 
since April 2009 with 2500 mg/kg weekly over 8 hours, and later modified to administrations 
every 2 weeks for convenience. The twins were diagnosed at 3 years old with initial symp-
toms of hepatosplenomegaly, ataxia and seizure activity, and previously were treated with 
miglustat, without significant benefits. After 18 months of therapy, any objective improve-
ment was reported, and the disease continued to progress as evidenced by positron emission 
tomography (PET) imaging and neurological assessments [26]. Both patients were described 
a transient appearance of slight scattered nodules in lungs during bronchoscopy, which were 
identified as xanthomas, a deposition of yellowish cholesterol-rich material typical of NPD-C, 
resolved without treatment changes in IV therapy [32].
Use of 2-Hydroxypropyl-Beta-Cyclodextrin for Niemann-Pick Type C Disease
http://dx.doi.org/10.5772/intechopen.71970
101
In October 2010, the FDA allowed the addition of HP-β-CD IT administration at doses of 
350 mg every 2 weeks (initial dose 175 mg/2 weeks) [32, 33]. During the first months of con-
current IV/IT therapy, a significant improvement was observed in the validated NIH NPC 
Clinical Severity Score (NNCSS), as well as in the brainstem auditory evoked response 
(BAER) [33]. After 18 months, ICV route was authorized by FDA in the twins through an 
Ommaya reservoir system. One of them tolerated perfectly the ICV and continues today with 
the treatment, whereas in her sister, ICV was discarded by insertion bleeding and IT route 
was recovered. Both patients have experienced improvements in alertness, swallow, head 
control, and ataxia [32, 34].
The second reported use of IV HP-β-CD (Trappsol® Cyclo™) was in two Brazilian sisters at 
age of 12 and 16 years old with concomitant miglustat treatment. Dr Vieira employed the 
same IV protocol with a dose escalation from 1200 to 2500 mg/kg/week. Both patients showed, 
after 1 year of treatment, objective benefits in PET and NNCSS, as well as improvements 
in motor dysfunction, cataplexy, psychiatric symptoms, behavior, cognitive functions, and 
memory [27]. Two later reports informed about the simultaneous treatment with IV weekly 
and IT twice monthly at least 3 years, maintaining the good results previously reported with 
IV infusions [35, 36]. No adverse events (AEs) were reported, although the published data 
were limited and only congress abstracts were reported [27, 35, 36].
Two reported cases of Japanese NPD-C patients diagnosed at 2 months and 13 years were 
initially treated at 4 and 14 years old with the IV “Oakland protocol”, with doses from 80 mg 
to 2500 mg/kg/three or two times a week, respectively [37, 38]. These were the first published 
cases of VTS-270 use in NPD-C. The younger patient reported with IV administration, a mild 
decrease in hepatosplenomegaly and temporary improvements in EEG and stabilization of 
disability scores the first 6 months. However, rest of the 2 years with only IV infusions a 
rapid progression of neurological dysfunction and worsening of swallow, speech, rigidity, 
and seizures were reported [37]. Furthermore, repeated fever with transient diffuse pulmo-
nary cloudiness episodes were observed, an AE probably related to HP-β-CD IV infusion. 
After 2 years of IV therapy, IT first and later ICV administrations were combined with IV 
infusions [38]. The combined therapy obtained objective benefits in EEG, PET and magnetic 
resonance spectroscopy (MRS), and CSF T-tau level reduction. Furthermore, improvements 
in eye movement, language, and speech were reported, as well as and stabilization of clinical 
progression for 2 years. No AEs were detected over the 2 years of IV/ICV combined therapy.
The other patient, a girl of 14 years old at the time of HP-β-CD therapy onset, was only treated 
with IV infusions for 3 years. At the beginning of the treatment the patient showed benefits in 
EEG, MRS and visual evoked potential (VEP), but after 3 months disappeared. A decrease in 
hepatosplenomegaly was observed in abdominal ultrasound and body computed tomography 
(CT). The general condition, neurological tests, and seizure control were stabilized with ther-
apy, reporting only an improvement in alertness. Tolerance of IV therapy was excellent [37].
Drs Hrynkow and Hastings recently reported in a Congress the clinical experience with 
11 patients initially treated with IV HP-β-CD more than 6 years [39]. Two of these patients 
were only treated with IV infusions, whereas in nine patients IT therapy was added later. 
In the two patients with only IV therapy, one showed a progression in NNCSS similar 
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than previous scores before initiation, whereas the other patient reported a stabilization of 
NNCSS after IV therapy. In two patients with IV/IT therapy significant decrease in NNCSS 
were observed comparing pre and post-therapy scores. In the other seven patients was 
only available post-therapy information, showing in most of the cases an initial de decrease 
in NNCSS followed with a progressive increase. Other significant improvements were 
reported, as reduction in hepatomegaly, restoration of language skills, resolution of inter-
stitial lung disease and improvements in fine motor control. The tolerability was favorable, 
although some AEs were reported during 6 years of therapy (Table 1).
Despite the positive results observed in the compassionate use of IV HP-β-CD [26, 27, 32–39], 
there is no clear evidence to date that IV route has a clinical benefit in CNS symptoms of 
NPD-C in humans. Most of the reports with neurological improvements combined the use of 
IV and IT/ICV administrations, making it impossible to demonstrate that these benefits were 
exclusively associated to IV and not IT/ICV. In addition, doses 1000 times larger than the IT 
dose should be required to achieve the same concentrations in the CSF reached by IT admin-
istration with IV infusions of HP-β-CD. This dosage would probably be unsafe in humans.
5. Experience in humans: efficacy of the intrathecal administration of 
cyclodextrin
The IT route was proposed when the efficacy of IV infusions of HP-β-CD was questioned. The 
first cases of IT administrations were combined with IV, as we previously explained [33–37, 
39]. At this point, IT route was proposed as the main route for NPD-C therapy. The first 
published case report of IT HP-β-CD (Trappsol® Cyclo™) administration was a Spanish girl 
diagnosed and treated at 2 years old. The dosage varied from 200 to 450 mg every 2 weeks. At 
38 months an IT Ommaya reservoir (IT-OR) was implanted in order to increase patient conve-
nience and reduce number of punctures, modifying the dosage to 400 mg every 2 weeks. The 
patient showed improvements in BAER test, whereas neurological symptoms and NNCSS 
were stabilized. The patient suffered two episodes of seizures with a fever with IT therapy, 
resolved without any change in treatment and which could be related to HP-β-CD, the pro-
cedure or the disease [40].
AEs associated with administration AEs recognized as features of 
NPD-C
Other AEs of interest
Rash
Generalized rash (trunk, elbow)
Tremor/chills/vomiting/fever
Headache
Nausea
Stomach pain
Seizures
Pneumonia
Thrombocytopenia
Viral illnesses
Viral syndrome
Port-a-Cath infection
Removal of Ommaya 
Reservoir
Post-operative delayed 
Parenchymal hemorrhage
Meningitis
Table 1. Adverse events related to IV with/without IT HP-β-CD administrations.
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Dr. Berry-Kravis reported the clinical outcomes of the use of IT HP-β-CD (Trappsol® Cyclo™) 
in three patients with NPD-C in several congresses [41–43]. Two of them were a couple 
siblings of 14 and 15 years old who were unable to be enrolled in the Phase 1 clinical trial 
(NCT01747135) and were treated as a compassionate use. The younger sibling with doses 
from 200 to 500 mg every 2 weeks obtained improvements in NNCSS, instrumented timed 
up and go (gait test) and Mullen Scales of Early Learning (cognitive scale), as well as ben-
efits in cognitive functions, seizures, swallow, language and speech [40–43]. The other sibling 
received doses from 200 to 600 mg every 2 weeks but the benefit was poor, with stabiliza-
tion of NNCSS, CFS reduction of lysozyme and improvement in cognitive functions [40–43]. 
After the first three IT infusions were reported post lumbar puncture headache and vomiting 
in both siblings, but it was not related to the drug and disappeared after a switch to use of 
Whitacre spinal needles. The clinical information regarding the third patient was insufficient 
to evaluate the efficacy, although an improvement in balance and gait was reported after 
1 year treated with doses from 200 to 400 mg every 2 weeks [43].
The use of IT HP-β-CD with a fixed dose of 200 mg every 2 weeks was reported by Maarup 
et al. in a single case report. After 18 months of the therapy, the boy showed an improve-
ment in vertical gaze (eye movement) and the consequent decrease in the NNCSS. This study 
also reported an increase in 24-OH cholesterol, a biomarker of cholesterol redistribution in 
CNS. On the other hand, an AE was associated to HP-β-CD administration, the well-known 
hearing loss to high frequency [44].
The use of IT-OR HP-β-CD in two Spanish boys diagnosed of NPD-C at 6 and 10 years old 
was briefly reported in congresses [45, 46]. The first patient was treated at 11 years with doses 
from 125 to 525 mg (Trappsol® Cyclo™) every 2 weeks for at least 37 months. Benefits in 
muscle tone and a decrease in seizures frequency were observed with IT-OR therapy. Initially 
was reported an improvement in BAER test, although it was alternated with auditory dete-
riorations [32, 45]. In the other case report, a 16 years patient received IT-OR fixed-doses 
of 350 mg every 2 weeks for 20 months. The objectives results included BAER tests and 
NNCSS. Furthermore, improvements in language and speech, ataxia and quality of life were 
obtained. The most relevant toxicities were intermittent fever and a suspicion of chemical 
meningitis [32, 46].
A recently published article described the IT therapy of a young NPD-C girl of 22 months 
[47]. The dosage of HP-β-CD was 175–325 mg every 2 weeks for 20 months. The treatment 
only achieved improvements in visual contact and motor function with the first doses, as well 
as slight retardation of disease progression and in the NPD-C disability scale during the first 
year. After the first year, MRI showed a progression of cerebral atrophy, which was consis-
tent with a clinical disease progression (epilepsy, dysphagia, and worsening motor function). 
Despite the initial response and the absence of AEs, the IT HP-β-CD was discontinued after 
20 months by lack of efficacy.
The employment of HP-β-CD in adult-onset NPD-C has been described with variable results 
in two publications [48, 49]. Sakiyama et al. reported the IT treatment (VTS-270) of two adult 
patients of 37 and 28 years with doses from 100 to 400 mg every month. The older patient 
showed better eye movement and neurological stabilization, whereas the younger patient 
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reported improvement in NPD-C scales, balance and gait, language and speech, and swallow. 
In addition, reductions in oxysterol serum concentrations were observed in both patients, a 
sterol storage biomarker. No AEs were reported in these patients [32, 48]. The worse out-
comes observed in two cases reported by García-Robles et al. could be related to the age (49 
and 39 years old) and advanced disease at the HP-β-CD onset. The dosages of IT HP-β-CD 
(Trappsol® Cyclo™) ranged from 175 to 700 mg and 50 to 875 mg every 2 weeks, also using 
IT-OR route in the second patient. Any objective or subjective improvements were reported 
in both patients. The older patient received only four doses with optimal tolerance, but 
HP-β-CD therapy was discontinued when neuropsychiatric symptoms progressed. The other 
patient suffered two episodes of toxic meningitis as well as worsening respiratory symptoms 
and swallow. After second chemical meningitis and neurologic progression of the disease, 
HP-β-CD treatment was discontinued [49].
6. Experience in humans: ongoing clinical trials
Four clinical trials using cyclodextrin for the treatment of NPD-C have been found. One of 
them has been completed and their results have been published [50] and three are currently 
ongoing and no preliminary results have been yet published.
• Intrathecal 2-hydroxypropyl-β-cyclodextrin (VTS-270) for Niemann-Pick type C1 (NPC-1) 
disease. A non-randomized, open-label, Phase 1–2 trial. See ClinicalTrials.gov Identifier: 
NCT01747135 [50].
Phase 1–2, non-randomized, open-label, study, to assess the tolerability, safety, feasibility, 
and PK of HP-β-CD administered IT monthly via lumbar injection to drug naive cohorts of 
NPC-1 patients at doses of 50 mg escalated to a maximum of 1200 mg. The objective is to deter-
mine an active dose of HP-β-CD as measured by changes in plasma 24-(S)-hydroxycholesterol 
(24(S)-HC) concentration and to evaluate the use of biomarkers and potential clinical out-
comes of NPC-1. NNCSS is used to assess clinical efficacy. The decision to dose-escalate 
is based on safety and biochemical data. Safety is assessed by the appearance of AEs with 
performance of clinical laboratory tests, physical examinations, and with special attention to 
audiological evaluation. Biochemical efficacy is measured by change from baseline in plasma 
24(S)-HC. The PK analysis is assessed for plasma HP-β-CD concentrations. This is the only 
clinical trials of HP-β-CD with published results.
Eligible patients were aged 2–25 years and had NPC-1 with neurological manifestations. 
Fourteen patients were enrolled from National Institutes of Health (NIH-cohort). Cohort size 
was three participants for initial IT doses of 50, 200, 300, 400, and 900 mg (only two patients) 
administrated IT every month. Three participants were initially dosed with 50 mg ICV via 
an Ommaya reservoir approximately 6 months prior to initiation of the IT trial. Use of the 
Ommaya reservoirs was discontinued due to P. acnes infection/colonization in two subjects. 
Due to this problem, initial protocol was amended and ICV route was changed by IT. After 
initial dosing at the specified cohort dose, participants were dose-escalated based on tolerance 
and safety data.
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As comparison control, a cohort of NPD-C subjects from Natural History study with longitu-
dinal assessments was employed. These patients were not on HP-β-CD treatment. To explore 
a scheme every 2 weeks, three additional subjects were recruited with the same criteria men-
tioned above in Rush University Medical Center (RUMC-cohort).
The primary outcome was changed in 24[S]-HC area under the curve (AUC8–72) response to drug administration compared with the response after saline administration. The AUC8–72 of plasma 24(S)-HC concentrations were established after its determinations at pre-dose, 8, 24, 
30, 48, and 72 hours post-dose after either HP-β-CD of saline infusion.
As a secondary objective, NNCSS was used to assess clinical efficacy. Audiological assess-
ments were obtained monthly before each infusion. Also the concentrations of fatty acid bind-
ing protein 3 (FABP3) and calbindin D in cerebrospinal fluid (CSF) were assayed.
Finally, 14 NIH-patients and 3 RUMC-patients were enrolled. Twenty-one patients with simi-
lar characteristics were identified from the historical database for comparing. For primary 
outcome (change in 24(S)-HC AUC8–72), 121 of 155 post-drug plasma value were greater than 
post-saline values. Despite the variability, the data suggest a dose-response relationship. All 
the patients of the study had either FABP3 or calbindin D, a significant negative linear regres-
sion slope (only one patient had a significant increase in calbindin D slope).
Regarding clinical efficacy, the total NNCSS for NIH-cohort increased at a slower rate than 
comparison cohort. These data show a significant reduction in disease progression in the 
cohort of HP-β-CD treated patients. In a secondary responder analysis, cohorts of treated 
and comparison subjects were classified as responders when their NNCSS minus hearing 
was stable or improved. Seven of 14 NIH-cohort subjects were classified as responders, 3 of 3 
RUMC-cohort subjects were classified as responders, and none of 21 patients of comparison 
cohort were classified as responders. Safety will be discussed in Section 7.
The added value of this study was to provide a neurological disease progression comparison 
among a cohort of NPD-C subjects treated with IT HP-β-CD and a control cohort of NPD-C 
subjects from Natural History study, indicating a decrease rate of neurological disease pro-
gression in the treated cohort. Moreover, this study provides information on the safety of IT 
administered HP-β-CD and the measurement of biomarkers provided additional support for 
decreased neuronal damage and improved neuronal cholesterol homeostasis.
• A Phase 2b/3 prospective, randomized, double-blind, sham-controlled trial of VTS-270 (HP-
β-CD) in subjects with neurologic manifestations of Niemann-Pick type C1 (NPC-1) disease. 
(See ClinicalTrials.gov identifier: NCT02534844 and EudraCT Number: 2015-002548-15).
Multicenter, multinational, prospective, randomized, double-blind, sham-controlled, three-
part, efficacy and safety trial of HP-β-CD, administered by the lumbar IT route every 2 weeks, 
with a planned enrollment of approximately 51 subjects with NPC-1 disease. This study is 
ongoing, but not recruiting participants (male or female subjects, aged 4–21 years of age at 
time of screening with onset of neurological symptoms prior to 15 years of age).
This study has three parts with different objectives. The objective of Part A is to select the 
dose of HP-β-CD to be used in Part B and Part C. Three different HP-β-CD lumbar IT doses 
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(900, 1200, and 1800 mg) will be administered IT every 2 weeks for 8 weeks and 2 weeks for 
observation in 9 subjects; 3 subjects will receive sham treatment. The criteria for dose selection 
include safety and tolerability including a thorough audiological evaluation.
The objective of Part B is to evaluate, in a double-blind sham-controlled design, the progres-
sion of the neurologic manifestations of NPC-1 disease based on changes in the composite 
efficacy outcome (consisting of four components of the NNCSS: ambulation, fine motor skills, 
cognition, and swallowing), after 52 weeks of treatment in comparison to baseline. Part B will 
evaluate the safety and efficacy of the dose selected from Part A compared to sham control in 
51 subjects (randomized 2:1), including the 12 subjects from Part A.
The objective of Part C is to evaluate the long-term safety, tolerability, and efficacy of the dose 
selected for Part B. This part is an open-label extension with IT treatment every 2 weeks to 
subjects who either complete Part B or are subjects in Part B who have met rescue therapy 
criteria. Additionally, subjects who are currently active in the NIH-sponsored Phase 1 pro-
tocol (NCT01747135, see above) will also be eligible to participate upon completion of their 
participation in the Phase 1 study. In this part, subjects will receive treatment until licensed 
product or end of the program.
The primary outcome measure of the study is NNCSS with a time Frame of 52 weeks. Data 
for NPD-C score rating will be provided to a centralized independent blinded rater, who will 
analyze all NPD-C information for all subjects and assign the NNCSS rate. As secondary out-
come measures are: clinician and caregiver clinical global impression of change, time to get 
up and go test, 9-hole peg test, percentage of patients with clinical worsening, and European 
Quality of Life-5 dimensions quality of life rating (EQ-5D QoL). Moreover, CSF and plasma 
biomarkers will be measured.
The design enables a selection of best dose based on efficacy, safety, and tolerability accord-
ing to an evaluation by a Committee. The dose chosen will be evaluated using changes in 
a composite efficacy outcome in order to assess the neurologic progression in participants. 
Highlight is that, it is the first study that uses quality of life rating. Moreover, assessment 
of biochemical markers of response and also due to a sufficient dosing duration will be per-
formed to assess the effectiveness of HP-β-CD in NPC-1. This is a global, multi-site study 
with the largest planned number of participants, and this will allow a better knowledge about 
NPD-C and efficacy treatment.
• A Phase I/II study to evaluate the safety and pharmacokinetics of intravenous Trappsol Cy-
clo (HP-β-CD) in patients with Niemann-Pick disease type C (NPC-1) and the pharmacody-
namic effects of treatment upon markers of cholesterol metabolism and clinical outcomes 
(see ClinicalTrials.gov Identifier: NCT02912793 and EudraCT Number: 2015-005761-23).
Phase 1/2, double-blind, randomized, multicentre, parallel group study based on data avail-
able and information from the administration via compassionate/named patient use in 
patients with NPC-1, and information of other cyclodextrin products in the literature. The 
study has two stages: the primary objective of Stage 1 is to compare the plasma pharmacoki-
netics (PK) of three different doses of IV HP-β-CD in the prevention/delay of NPC-1 progres-
sion whereas Stage 2 is to evaluate their efficacy and tolerability in the management of clinical 
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 manifestations. Secondary objectives include investigation of the effect of three different doses 
of HP-β-CD IV upon serum and lymphocytic markers of cholesterol metabolism (Stages 1 and 
2) and evaluation of concentrations in the CSF following IV administration (Stage 1), evalu-
ation of the impact of treatment upon behavioral aspects and the impact of treatment upon 
measures of neurological function including ataxia, aphasia, and saccadic eye movements of 
NPC-1 (Stage 2). The outcome measures are: plasma and CSF concentrations of HP-β-CD fol-
lowing IV administration, serum cholesterol markers, global impression of disease, quality of 
life scores, change in NNCSS, and changes in hepatic and splenic morphology.
In order to achieve these objectives, the primary endpoint of Stage 1 is plasma concentrations 
(at 0, 2, 4, 6, and 8 hours after the start of infusion and 30 minutes, 1, 2, 4, 8, and 12 hours 
after the end of the infusion) of HP-β-CD during and following infusion to evaluate time to 
maximum concentration (T max), maximum concentration (Cmax), volume of distribution 
and elimination half-life (t1/2). The primary endpoint of Stage 2 is the change from base-line in global impression of disease severity at 48 weeks and the proportion of patients at 
48 weeks with a reduction from baseline of at least one point in two or more domains of the 
NNCSS.
Patients taking miglustat are not excluded of the study because this drug is an approved treat-
ment for NPC-1 in Europe and it would be unethical, but it is planned to balance randomiza-
tion across groups for its use.
This clinical trial is already recruiting patients in United Kingdom and it is planned to recruit 
12 patients (3 children of 2–11 years, 3 of 12–17, and 6 adults 18–64 years). Patients will be ran-
domized 1:1:1 to one of the three dose levels (1500, 2000, or 2500 mg/kg; four patients per dose 
level). Treatment will be administered over 8 hours by slow IV infusion at a concentration of 
250 mg/mL every 2 weeks. Patients completing Stage 1 of the study will continue into Stage 2 
and receive treatment for 48 weeks.
The design enables early assessment of biochemical markers of response and also due 
to a sufficient dosing duration, to assess the effectiveness of HP-β-CD in NPC-1 and its 
pharmacokinetics.
• A Phase I study to evaluate the single and multiple-dose pharmacokinetics of intravenous 
Trappsol Cyclo (HP-Beta-CD) in patients with Niemann-Pick disease type C (NPC-1) and 
the effects of dosing upon biomarkers of NPC disease. (See ClinicalTrials.gov Identifier: 
NCT02939547).
Phase I, double-blind, randomized, single-center, parallel group study based on informa-
tion and data available from the administration of HP-β-CD via compassionate/named 
patient use in patients with NPC-1, and data on other cyclodextrin products in the scientific 
literature.
The study has a first phase of screening (up to 4 weeks), a treatment phase of 12 weeks and 
a later phase of follow-up of 4 weeks. The primary objective is to compare the plasma phar-
macokinetics of single and multiple doses of two different levels of IV HP-β-CD. Secondary 
objectives include investigation of the effect of different doses of IV HP-β-CD upon serum and 
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lymphocytic markers of cholesterol metabolism and evaluation of HP-β-CD concentrations in 
the CSF following IV administration, evaluation of the impact of treatment upon measures of 
neurological function including aphasia, ataxia, and saccadic eye movements, and the impact 
of treatment upon behavioral aspects of NPC-1.
This study is currently recruiting participants. It is planned to recruit a total of 12 patients (all 
adults) which will be randomized 1:1 to one of the two dose levels (1500 mg/kg or 2500 mg/kg; 
6 patients per dose level). Treatment will be administered every 2 weeks by slow IV infusion 
over 8 hours. Patients will receive treatment for a total of 12 weeks.
As primary outcome measures are pharmacokinetics parameters: Tmax, Cmax, volume of 
distribution, and t1/2 of HP-β-CD in plasma from NPC-1 patients by measurement at pre-infusion then 2, 4, 6, 8, 8.5, 9, 10, 11, 12, 16, and 20 hours after the start of the infusions at weeks 
1 and 12.
The design of the proposed study thus enables a better knowledge about pharmacokinet-
ics of IV HP-β-CD administration, an early assessment of potential biochemical markers of 
response but allows for a sufficient dosing duration to enable the short-term effectiveness of 
HP-β-CD in NPD-C to be assessed.
In conclusion, there is a published clinical trial results, using IT administration of HP-β-CD 
and shows moderate response thought slowed disease progression with an acceptable safety 
profile. Another IT HP-β-CD clinical trial and two IV HP-β-CD clinical trials are ongoing but 
not results are been published yet. Regarding the route of administration, exist a debate, and 
treatment with HP-β-CD has used four different paradigms: IV only, IV followed by the addi-
tion of IT sequential, IV and IT initiated concurrently, and IT only. The main reason for IT 
route is that HP-β-CD does not cross the BBB, however, in animal models systemic HP-β-CD 
positively affects CNS disease thus CNS penetration may not be essential for neurologic effi-
cacy. The ongoing clinical trials will lead to an improvement in knowledge of HP-β-CD for 
NPD-C treatment, setting the best route, dose and posology for NPD-C patients.
7. Experience in humans: potential toxicities of the different 
administration routes
There are three possible administration routes for HP-β-CD: IV, IT, or ICV via an Ommaya 
reservoir. Some adverse events observed could be related to the administration route, the 
disease progression, or the cyclodextrin itself.
The review performed by the EMA regarding the use of HP-β-CD as an excipient indicated 
that the IV administrations had low toxicity, being the most prevalent issue of the renal 
toxicity, especially with high doses [51]. However, any patients showed renal toxicity with 
HP-β-CD therapy [32]. This was the first route employed, but later a change to IT route was 
requested due to the discovery that HP-β-CD not cross the BBB and only a little quantity is 
able to enter to the brain [21, 24, 25, 30].
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Based on animal models, ICV route was proposed as an alternative with potential benefits 
and this route was chosen in the Phase I clinical trial (NCT01747135) using an Ommaya 
 reservoir to facilitate the administration. Unfortunately, complications due to colonization 
by P. acnes led to change ICV route to IT [52]. Currently, IV route is being tested in two ongo-
ing clinical trials, whereas IT route is analyzed in another ongoing trial and in the recently 
published trial [50].
Megías-Vericat et al. reviewed the initial published cases of HP-β-CD treatment [32]. Regarding 
safety, 11 of 17 NPD-C patients included suffered AEs. Of the 17 AEs reported, 6 were related 
to the route of administration, specifically with the IT and ICV routes and 10 of them could be 
attributed by HP-β-CD. Six AEs associated to the route were: CNS bleed related to insertion of 
the Ommaya reservoir system in a patient treated with ICV HP-β-CD led to ICV administra-
tion suspended [34]; post lumbar puncture headache and vomiting resolved with switching a 
Whitacre spinal needles [41–43]; post lumbar puncture pain, headache, nausea, and vomiting 
resolved with symptomatic and postural treatment [44]; seizures with fever resolved with-
out changes in treatment [40] and aspiration pneumonia; febrile syndrome; and candidiasis 
resolved with antibiotic and antifungal treatment [49].
Among AEs related to HP-β-CD itself, loss of hearing was reported in four reported cases of 
IT infusions [41–45], although it proved reversible in two of them. These patients were admin-
istered with reduced doses of HP-β-CD after hearing recovery, two times in one of them. In 
other two patients, despite delaying the next dose, hearing loss was not reversed. This AE was 
also observed in animal studies with IT [18], ICV [53], and intracisternal [25] routes of admin-
istration. At the dosage employed, hearing loss is an expected AE, as well as a well-known 
NPD-C symptom. At the clinical trial recently published, loss of hearing was reported in all 
the participants [50].
Four patients suffered from fever two or more times after HP-β-CD administrations [37, 
40, 46, 49]. In one case, fever was accompanied by seizures [40], whereas another patient 
showed an infusion reaction with fever and transient diffuse pulmonary cloudiness [37]. In 
one patient, after intermittent fever episodes, a diagnosis of chemical meningitis was made 
after bacterial meningitis was discarded. The IT-OR was withdrawn, and HP-β-CD was rein-
troduced 2 months later because the patient’s condition worsened [46]. Other patient showed 
two episodes of chemical meningitis (bacterial meningitis was discarded in both cases) after 
IT and IT-OR HP-β-CD administrations, although both were resolved quickly and without 
consequences [49]. This AE could be related to the method of administration or disease symp-
toms and not to HP-β-CD. However, the chemical meningitis observed seems to be associated 
to the drug after analyzed with the Naranjo algorithm [49]. Some acute neurological effects 
after the infusion of high doses that resolve after few days were described by some investiga-
tors in conferences (but unpublished yet).
Regarding the results of the first clinical trial published, no serious AEs were observed [50]. 
Marked expected AE included: ototoxicity (14 of 14 patients) and post lumbar puncture head-
ache (9 of 14 patients). Among unexpected AE included, post-administration unsteadiness 
and fatigue occurs at doses above 600 mg. The degree of impairment varied between subjects 
but usually was transient and occurred 24–72 hours after administration.
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Sensorineural hearing loss was present in all subjects of NIH-cohort (14 patients) and 2 of 3 
RUMC-cohort, and according to the study results, it was associated with the administration 
of HP-β-CD. Moreover, the data obtained suggest that there is greater HP-β-CD ototoxicity in 
subjects who have not yet lost hearing due to NPD-C itself. Also, tinnitus was present in 6 of 
14 patients in NIH-cohort and 1 of 3 in RUMC-cohort [50].
8. Conclusions
Until now, NPD-C treatment has been supportive and symptomatic with miglustat as the 
only disease-specific drug approved in some countries. HP-β-CD is a new option under inves-
tigation with two different products, Kleptose® and Trappsol Cyclo®, which are not chemi-
cally equivalent and therefore may not be biochemically equivalent or lead to comparable 
formulations from a clinical development perspective.
Based on preclinical animal studies, HP-β-CD has been tested in humans affected by 
NPD-C during the last years. In compassionate use outside clinical trials, HP-β-CD has 
been administrated with either IV, IT, or ICV. Despite the positive results observed with 
IV HP-β-CD, there is no clear evidence to date that IV route has a clinical benefit in CNS 
symptoms of NPD-C as most of the reports combined IV and IT/ICV administrations. 
The reported cases of IT infusions obtained higher improvements reducing the disease 
progression.
The results of a recently published clinical trial reproduced the findings observed with IT 
route. The trial has shown slowing of NPD-C progression in 14 patients with a dose escala-
tion of IT HP-β-CD administrated monthly as well as in 3 patients with administration every 
2 weeks regarding a historical comparison cohort.
Some adverse events observed could be related to the administration route, the disease pro-
gression, or the cyclodextrin itself. The safety profile of HP-β-CD seems acceptable, being the 
loss of hearing (related to HP-β-CD) the most frequent adverse reported in the clinical trial 
and published cases. However, some severe toxicities have been reported including chemical 
meningitis and fever although not in published clinical trial.
Furthermore, there are currently two IV HP-β-CD and one IT HP-β-CD ongoing clinical trials 
without published results. The findings of these trials will lead to an improvement in knowl-
edge of HP-β-CD for NPD-C, setting the best route, dose, and posology. Currently, the short 
experience with HP-β-CD suggested that it could be effective in the management of NPD-C 
but the results of ongoing clinical trials will be definitive.
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